Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bridgebio Pharma Inc (NQ: BBIO ) 24.40 -0.56 (-2.24%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,073,154 Open 24.83 Bid (Size) 24.40 (64) Ask (Size) 24.41 (1) Prev. Close 24.96 Today's Range 24.32 - 25.06 52wk Range 21.62 - 44.32 Shares Outstanding 160,500,999 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) August 08, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BBIO Stock Earnings: BridgeBio Pharma Misses EPS, Misses Revenue for Q2 2024 August 01, 2024 BBIO stock results show that BridgeBio Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Performance YTD -39.68% -39.68% 1 Month -12.83% -12.83% 3 Month -18.91% -18.91% 6 Month -34.43% -34.43% 1 Year -14.11% -14.11% More News Read More BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update August 01, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer July 23, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire Why BridgeBio Pharma Stock Is Trading Lower Tuesday June 04, 2024 Via Benzinga BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) July 05, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday June 24, 2024 Via Benzinga Masters In Trading - Saturday, June 22 June 22, 2024 Via Talk Markets BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) June 18, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings June 12, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference June 06, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings June 05, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire The 3 Best Biotech Stocks to Buy in June 2024 June 05, 2024 Via InvestorPlace BridgeBio Pharma Shares One Year Data From Dwarfism Candidate June 04, 2024 Via Benzinga BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results June 04, 2024 Via Investor's Business Daily BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia June 04, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 June 03, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) May 29, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire 7 Biotech Stocks to Put on Your Breakthrough Radar May 27, 2024 Via InvestorPlace BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting May 24, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 May 14, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified May 13, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.